ShareValue scores for KRYS: Valuation 30, Quality 82, Growth 58, Health 67.

Krystal Biotech Inc logo

KRYS
NASDAQ

Krystal Biotech Inc

$315.82(+0.15%)

Updated

Loading chart...
Sentiment

Pulse

Rating

Moderate

Trap Risk

P/E to median

Not enough data
Valuation
30
Overvalued

vs US-listed mid-cap Healthcare stocks

Price vs Value
Quality
82
Strong
Business Strength
Growth
58
Moderate
Revenue & Earnings
Health
67
Moderate
Financial Stability
Price trend
54
Neutral
Separate from the four scores

Company Details

About

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Score Analysis

AI Investment Thesis

Data as of:Nov 20, 2026

By using ShareValue.ai you agree to our Terms and Privacy Policy. Educational platform, not investment advice.